Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma

被引:0
作者
Cimpean, Anca Maria [1 ]
Raica, M. [1 ]
Suciu, C. [1 ]
Tatucu, Diana [1 ]
Sarb, Simona [1 ]
Muresan, Anca Maria [2 ]
机构
[1] Victor Babes Univ Med & Pharm, Dept Hist & Cytol, Timisoara 300041, Romania
[2] Victor Babes Univ Med & Pharm, Dept Pathol, Timisoara 300041, Romania
关键词
invasive breast carcinoma; immunohistochemistry; prognosis; VEGF;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
VEGF is a potent mitogen for endothelial cells and also acts in an autocrine and paracrine manner for development of tumor cells in breast cancer. Correlations between VEGF and some clinicopathologic findings were largely studied but results were controversial. Our purpose was to find if VEGF could be used as individual prognostic factor in invasive breast carcinoma. We included in our study 35 cases of invasive breast carcinoma, which were immunostained for VEGF using monoclonal antibodies anti-VEGF clone VG1. The assessment of VEGF expression used a scoring system, which included an intensity parameter correlated with percent of positive tumor cells. We found positive correlation between ductal invasive carcinoma type of breast cancer and VEGF expression. In addition, presence of inflammation associated with breast malignancies had a significant correlation with VEGF positive staining. Because of these correlations found in our study, we concluded that VEGF could not be used as individual prognostic factor in invasive breast carcinoma.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 45 条
[1]  
Adams J, 2000, CANCER RES, V60, P2898
[2]   Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription [J].
Akiri, G ;
Nahari, D ;
Finkelstein, Y ;
Le, SY ;
Elroy-Stein, O ;
Levi, BZ .
ONCOGENE, 1998, 17 (02) :227-236
[3]  
Ali SH, 2000, CANCER RES, V60, P7094
[4]   Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity [J].
Balasubramanian, Sabapathy P. ;
Cox, Angelo ;
Cross, Simon S. ;
Higham, Sue E. ;
Brown, Nicola J. ;
Reed, Malcolm W. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (05) :1009-1016
[5]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[6]  
Bogin L, 2002, CANCER RES, V62, P1948
[7]  
Borgström P, 1999, ANTICANCER RES, V19, P4203
[8]  
Byrne GJ, 2007, ANTICANCER RES, V27, P3481
[9]   FDA drug approval summary:: Bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer [J].
Cohen, Martin H. ;
Gootenberg, Joe ;
Keegan, Patricia ;
Pazdur, Richard .
ONCOLOGIST, 2007, 12 (06) :713-718
[10]   Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth, factor receptor-2 levels as a surrogate biomarker for tumor growth [J].
Ebos, John M. L. ;
Lee, Christina R. ;
Bogdanovic, Elena ;
Alami, Jennifer ;
Van Slyke, Paul ;
Francia, Giulio ;
Xu, Ping ;
Mutsaers, Anthony J. ;
Dumont, Daniel J. ;
Kerbel, Robert S. .
CANCER RESEARCH, 2008, 68 (02) :521-529